Kaplan-Meier Analysis using the Leucegene AML RNA-Seq Prognostic Cohort [n = 373]
The following tool lets you explore the relationship between gene expression and clinical outcome in terms of survival. The cohort is split into 2 categories based on median gene expression value. The survival cohort consists of 373 diagnostic AML samples (excluding acute promyelocytic leukemia). Gene expression was generated using STAR/RSEM and GRCh38 (Gencode32) and is expressed in TPM.
IMPORTANT: Please note that the data displayed on this website is not for diagnostic purposes and is not a substitute for a doctor's advice. Please consult your doctor with any questions. The information provided here is only for informational and educational purposes. Because the graphs on this website are from single-variable analyses, they cannot be used to make predictions about your health.